论文部分内容阅读
目的观察罗格列酮和二甲双胍治疗2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)的临床疗效。方法将60例T2DM合并NAFLD患者随机分为治疗组和对照组,治疗组口服罗格列酮4mg,1次/d;对照组口服二甲双胍0.5g,3次/d;共6个月。观察两组治疗前后体重、肝功能、血脂、胰岛素抵抗指数的变化。结果两组治疗后体重、肝功能、血脂、胰岛素抵抗指数较治疗前明显改善,差异有统计学意义(P<0.05),治疗组效果更明显。结论罗格列酮能够治疗T2DM合并NAFLD患者,通过改善靶组织对胰岛素的敏感性,减轻非酒精性脂肪肝的胰岛素抵抗,调节血脂,疗效优于二甲双胍。
Objective To observe the clinical efficacy of rosiglitazone and metformin in the treatment of type 2 diabetes mellitus (T2DM) with non-alcoholic fatty liver disease (NAFLD). Methods Sixty T2DM patients with NAFLD were randomly divided into treatment group and control group. The treatment group received oral rosiglitazone 4 mg once daily, while the control group received metformin 0.5 g three times daily for 6 months. The changes of body weight, liver function, blood lipid and insulin resistance index were observed before and after treatment. Results The body weight, liver function, blood lipids and insulin resistance index of the two groups were significantly improved after treatment (P <0.05), and the effect of the treatment group was more obvious. Conclusions Rosiglitazone can treat T2DM with NAFLD in patients with T2DM and NAFLD. It is more effective than metformin by improving the sensitivity of target tissues to insulin, reducing the insulin resistance of nonalcoholic fatty liver and regulating blood lipids.